“We found that we can move many of our staff offsite and go to remote workforce options,” says Scott Sellinger, MD.
At the 2021 LUGPA Annual Meeting, Scott Sellinger, MD, moderated the discussion, “Re-imagining Our Independent Urology Practices: What’s the New Normal?” The panel covered how the changes LUGPA facilitated for independent urology practices during the pandemic and what continued
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.